JP2023036695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023036695A5 JP2023036695A5 JP2022198455A JP2022198455A JP2023036695A5 JP 2023036695 A5 JP2023036695 A5 JP 2023036695A5 JP 2022198455 A JP2022198455 A JP 2022198455A JP 2022198455 A JP2022198455 A JP 2022198455A JP 2023036695 A5 JP2023036695 A5 JP 2023036695A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrocarbyl
- different
- same
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052805 deuterium Inorganic materials 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 102000051367 mu Opioid Receptors Human genes 0.000 claims 3
- -1 nitro, phenyl Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108020001612 μ-opioid receptors Proteins 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671235P | 2012-07-13 | 2012-07-13 | |
| US61/671,235 | 2012-07-13 | ||
| US201361789180P | 2013-03-15 | 2013-03-15 | |
| US61/789,180 | 2013-03-15 | ||
| US13/940,016 | 2013-07-11 | ||
| US13/940,016 US10017736B2 (en) | 2012-07-13 | 2013-07-11 | Method of inhibiting tau phosphorylation |
| JP2018189789A JP2019031520A (ja) | 2012-07-13 | 2018-10-05 | τリン酸化を阻害する方法 |
| JP2021089538A JP2022000421A (ja) | 2012-07-13 | 2021-05-27 | τリン酸化を阻害する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021089538A Division JP2022000421A (ja) | 2012-07-13 | 2021-05-27 | τリン酸化を阻害する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023036695A JP2023036695A (ja) | 2023-03-14 |
| JP2023036695A5 true JP2023036695A5 (enExample) | 2023-06-26 |
| JP7419486B2 JP7419486B2 (ja) | 2024-01-22 |
Family
ID=49914489
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521820A Active JP6417324B2 (ja) | 2012-07-13 | 2013-07-11 | τリン酸化を阻害する方法 |
| JP2018000198A Active JP6630374B2 (ja) | 2012-07-13 | 2018-01-04 | τリン酸化を阻害する方法 |
| JP2018189789A Pending JP2019031520A (ja) | 2012-07-13 | 2018-10-05 | τリン酸化を阻害する方法 |
| JP2021089538A Pending JP2022000421A (ja) | 2012-07-13 | 2021-05-27 | τリン酸化を阻害する方法 |
| JP2022198455A Active JP7419486B2 (ja) | 2012-07-13 | 2022-12-13 | τリン酸化を阻害する方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521820A Active JP6417324B2 (ja) | 2012-07-13 | 2013-07-11 | τリン酸化を阻害する方法 |
| JP2018000198A Active JP6630374B2 (ja) | 2012-07-13 | 2018-01-04 | τリン酸化を阻害する方法 |
| JP2018189789A Pending JP2019031520A (ja) | 2012-07-13 | 2018-10-05 | τリン酸化を阻害する方法 |
| JP2021089538A Pending JP2022000421A (ja) | 2012-07-13 | 2021-05-27 | τリン酸化を阻害する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US10017736B2 (enExample) |
| EP (1) | EP2882428B1 (enExample) |
| JP (5) | JP6417324B2 (enExample) |
| DK (1) | DK2882428T3 (enExample) |
| ES (1) | ES2716049T3 (enExample) |
| WO (1) | WO2014011917A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014012054A1 (en) * | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| GB201312499D0 (en) * | 2013-07-12 | 2013-08-28 | Isis Innovation | Therapeutic compounds |
| US9433604B2 (en) | 2013-10-08 | 2016-09-06 | Pain Therapeutics Inc. | Method for inhibiting growth of cancer cells |
| CN104030933A (zh) * | 2014-05-16 | 2014-09-10 | 烟台恒迪克能源科技有限公司 | 一种β-异烷醇基氨基戊酸环己胺的合成方法 |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| AU2017340403B2 (en) | 2016-10-05 | 2022-03-17 | The United States as Represented by the Department of Veterans Affairs | Small molecule AMPK activators |
| US12186307B2 (en) | 2019-02-13 | 2025-01-07 | Yale University | Methods of treating epilepsy |
| US11370791B2 (en) | 2019-02-21 | 2022-06-28 | Cassava Sciences, Inc. | Solid polymorphs of a FLNA-binding compound and its hydrochloride salts |
| EP4027987A4 (en) | 2019-09-10 | 2023-11-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods and materials for increasing level of phosphorylated ampk protein |
| US20230045629A1 (en) * | 2020-01-15 | 2023-02-09 | National University Corporation Tokai National Higher Education And Research System | Treatment of progressive supranuclear palsy |
| AU2021376267A1 (en) * | 2020-11-03 | 2023-06-15 | Cassava Sciences, Inc. | Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4 |
| CN114252324B (zh) * | 2022-03-02 | 2022-05-13 | 中国人民解放军军事科学院军事医学研究院 | 一种方便使用的多孔脑片孵育装置 |
| WO2024151661A2 (en) * | 2023-01-10 | 2024-07-18 | Washington University | Methods of decreasing pathological neuroinflammation |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723442A (en) | 1970-12-31 | 1973-03-27 | Yoshitomi Pharmaceutical | 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes |
| US4981858A (en) | 1987-08-13 | 1991-01-01 | State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research | Optical isomers |
| DE3853758T2 (de) | 1987-10-05 | 1995-09-07 | Yamanouchi Pharma Co Ltd | Heterozyklische Spiroverbindungen und ihre Herstellung. |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| US5534520A (en) | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| ES2119174T3 (es) | 1993-01-28 | 1998-10-01 | Merck & Co Inc | Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas. |
| US6060469A (en) | 1995-11-23 | 2000-05-09 | Merck Sharp & Dohme Ltd. | Spiro-piperidine derivatives and their use as tachykinin antagonists |
| ATE255888T1 (de) * | 1998-06-01 | 2003-12-15 | Ortho Mcneil Pharm Inc | Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten |
| DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| DE60226874D1 (de) | 2001-07-23 | 2008-07-10 | Banyu Pharma Co Ltd | 4-oxoimidazolidin-2-spiro piperidin derivat |
| NZ560368A (en) | 2002-05-03 | 2008-11-28 | Israel Inst Biolog Res | Methods and compostions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| DE102004014304A1 (de) | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen |
| DE102004014296A1 (de) | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen |
| US8088787B2 (en) * | 2004-05-12 | 2012-01-03 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods related to the treatment of neurodegenerative and inflammatory conditions |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| US8614324B2 (en) | 2008-10-31 | 2013-12-24 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| US20100280057A1 (en) * | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| US8653068B2 (en) | 2009-10-30 | 2014-02-18 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| WO2009059225A2 (en) | 2007-11-02 | 2009-05-07 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a |
| CA2779261C (en) * | 2008-10-31 | 2015-03-24 | Pain Therapeutics, Inc. | Filamin a binding anti-inflammatory and analgesic |
| US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| US8580808B2 (en) | 2009-10-30 | 2013-11-12 | Pain Therapeutic, Inc. | Filamin A-binding anti-inflammatory analgesic |
| US20100279996A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| WO2010084499A2 (en) * | 2009-01-26 | 2010-07-29 | Israel Institute For Biological Research | Bicyclic heterocyclic spiro compounds |
| US20100280061A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| TWI374662B (en) * | 2009-05-18 | 2012-10-11 | Novatek Microelectronics Corp | Image processing circuit and method thereof |
| US8580809B2 (en) | 2009-10-30 | 2013-11-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
| WO2014028755A1 (en) * | 2012-08-16 | 2014-02-20 | Pain Therapeutics, Inc. | Benzazocine-ring compound inhibition of tau hyperphosphorylation |
-
2013
- 2013-07-11 EP EP13816713.5A patent/EP2882428B1/en active Active
- 2013-07-11 WO PCT/US2013/050126 patent/WO2014011917A2/en not_active Ceased
- 2013-07-11 US US13/940,016 patent/US10017736B2/en active Active
- 2013-07-11 JP JP2015521820A patent/JP6417324B2/ja active Active
- 2013-07-11 DK DK13816713.5T patent/DK2882428T3/en active
- 2013-07-11 ES ES13816713T patent/ES2716049T3/es active Active
-
2018
- 2018-01-04 JP JP2018000198A patent/JP6630374B2/ja active Active
- 2018-07-09 US US16/030,494 patent/US10760052B2/en active Active
- 2018-10-05 JP JP2018189789A patent/JP2019031520A/ja active Pending
-
2020
- 2020-08-28 US US17/006,338 patent/US11661580B2/en active Active
-
2021
- 2021-05-27 JP JP2021089538A patent/JP2022000421A/ja active Pending
- 2021-08-20 US US17/408,038 patent/US20210389298A1/en not_active Abandoned
-
2022
- 2022-12-13 JP JP2022198455A patent/JP7419486B2/ja active Active
-
2023
- 2023-05-24 US US18/323,075 patent/US20240117306A1/en not_active Abandoned
-
2024
- 2024-11-21 US US18/955,938 patent/US20250163372A1/en active Pending
- 2024-11-21 US US18/955,937 patent/US20250092361A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023036695A5 (enExample) | ||
| JP2022000421A5 (enExample) | ||
| JP2015523385A5 (enExample) | ||
| KR970704435A (ko) | 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands) | |
| CA2679232A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
| NZ590784A (en) | Pyrazolopyridine kinase inhibitors | |
| ZA200403087B (en) | MCH antagonists for the treatment of obesity. | |
| ATE300521T1 (de) | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern | |
| RU98118568A (ru) | Триарильные соединения | |
| ZA200403685B (en) | Cannabinoid receptor ligands. | |
| RU2000127751A (ru) | Противоопухолевое средство | |
| RU2003117476A (ru) | Аминотиазолы и их применение в качестве антагонистов рецептора аденозина | |
| JP2005538100A5 (enExample) | ||
| JP2004523561A5 (enExample) | ||
| RU2004130427A (ru) | Производные нитрозодифениламина и их фармацевтическое применение против патологий окислительного стресса | |
| JP2008515913A5 (enExample) | ||
| RU2000125568A (ru) | Производные циклоалкенов, их получение и применение | |
| JPS6197228A (ja) | ジヒドロピリジン類とａｃｅ阻害剤との配合物 | |
| HRP20110332T1 (hr) | TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 | |
| RU2002103876A (ru) | АМИНОБЕНЗОФЕНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕРЛЕЙКИНА IL-1β И ФАКТОРА НЕКРОЗА ОПУХОЛЕЙ TNF-α | |
| KR910004568A (ko) | 치환 n-(퀴놀린-2-일-메톡시)벤질-술포닐우레아 | |
| RU2006117627A (ru) | Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений | |
| RU2007112501A (ru) | Бензимидазольные производные, содержащие их композиции, их получение и применение | |
| US4442084A (en) | Analgesic and myotonolytic preparations | |
| WO1995024195A1 (en) | New use of quinoline-3-carboxamide compounds |